TacticScaleWhat GE Healthcare Technologies Does & How It Makes Money (GEHC)
Updated October 2026 · reflects GE Healthcare Technologies's latest reported financials
Medical imaging, patient monitoring and diagnostic drug maker. It earns money by selling imaging, ultrasound and patient-care equipment to hospitals and clinics, along with recurring revenue from services, consumables, digital software and diagnostic drugs that are used again with each scan.
How GE Healthcare Technologies makes money
It earns money by selling imaging, ultrasound and patient-care equipment to hospitals and clinics, along with recurring revenue from services, consumables, digital software and diagnostic drugs that are used again with each scan.
What GE Healthcare Technologies does
GE HealthCare Technologies is a medical technology company spun off from General Electric. It was incorporated in 2022 and is headquartered in Chicago. It develops, makes and sells products, services and digital solutions used to diagnose, treat and monitor patients in the U.S., Canada and internationally. It has four segments. Imaging covers molecular imaging, CT, MR, X-ray and women's health. Advanced Visualization Solutions covers ultrasound, image-guided therapy and surgical visualization. Patient Care Solutions covers monitoring, diagnostic cardiology, maternal infant care, anesthesia, consumables and digital tools. Pharmaceutical Diagnostics supplies contrast media and radiopharmaceuticals for radiology and nuclear medicine. The business pairs large equipment sales with recurring streams from service, consumables and imaging agents given before scans. It has a strategic collaboration with DeepHealth.
Products & services
- CT, MR and X-ray imaging systems
- Molecular imaging and women's health imaging
- Ultrasound and image-guided therapy systems
- Patient monitoring and anesthesia devices
- Diagnostic cardiology and maternal infant care
- Contrast media and radiopharmaceuticals
What is GE Healthcare Technologies worth?
On an owner-earnings DCF, GE Healthcare Technologies's most-likely value is about $76 versus a recent price near $66 (15% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$41) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
⚠ High leverage — net debt is 5.4× annual cash flow. Net debt is subtracted from this fair value, but refinancing at higher rates, principal timing, and share dilution aren’t modeled — the equity can be worth far less if cash flow weakens.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Shanghai United Imaging Healthcare (688271.SS) · Lantheus (LNTH) · Beijing Wandong Medical Technology (600055.SS) · RadNet (RDNT) · GE Aerospace (GE)